All Stories

  1. Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome
  2. The Importance of Standardized Assessment
  3. Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease
  4. Neuropsychiatric and young-onset as clinical determinants for a delayed HuntingtonÓ?s disease diagnosis
  5. Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset
  6. Determinants and impact of alexithymia on quality of life in Parkinson's disease
  7. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease?
  8. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
  9. Association between cardiometabolic comorbidities and Parkinson’s disease in a Mexican population
  10. Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic
  11. Documento de postura: la afectación de personal médico y de la salud en la pandemia de SARS-CoV-2
  12. Expanded and Independent Spanish Validation of the MDS‐Non Motor Rating Scale
  13. Experience with Creutzfeldt-Jakob disease in a single referral center in Mexico. Case series
  14. Attentional impairment in Parkinson’s disease is modulated by side of onset: Neurophysiological evidence
  15. Association between dopaminergic-induced complications and life satisfaction in ParkinsonÓ?s disease
  16. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson’s disease
  17. COVID-19 and Integrated Multidisciplinary Care Model in Parkinson’s Disease: Literature Review & Future Perspectives
  18. Pitfalls and caveats in the diagnostic pathway of people with ParkinsonÓ?s disease
  19. Experiencia con la enfermedad de Creutzfeldt-Jakob de un único centro de referencia en México. Análisis de una serie de casos
  20. Fellowship training: a collateral damage of Covid-19 pandemic
  21. Living with chronic illness scale in Parkinson's disease: Longitudinal metric properties and meaningful change
  22. Naturalistic Study of Depression Associated with Parkinson’s Disease in a National Public Neurological Referral Center in Mexico
  23. Satisfaction With Telemedicine Consultation as Follow-Up Visit in Patients with Parkinsonism and Essential Tremor in during the Covid-19 Pandemic
  24. Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
  25. Spotlight on non-motor symptoms and Covid-19
  26. The neuropsychiatry of Parkinson's disease: advances and challenges
  27. Editorial: Managing Parkinson's Disease With a Multidisciplinary Perspective
  28. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson’s disease
  29. Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana
  30. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  31. Pro- and anti-inflammatory response in neurological disorders associated to anti-glutamate decarboxylase antibodies
  32. Editorial: Measurement Tools for Clinical Assessment, Characterization and Neurorehabilitation of Parkinson's Disease
  33. Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life
  34. Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
  35. Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations
  36. Worldwide barriers to genetic testing for movement disorders
  37. Frontal functional connectivity and disease duration interactively predict cognitive decline in Parkinson's disease
  38. Incidencia y distribución geográfica de la enfermedad de Parkinson en México
  39. Malnutrition and Associated Motor and Non-motor Factors in People with Parkinson's Disease
  40. Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease
  41. Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations
  42. First report of pathogenic SGCE variants in Mexican patients with myoclonus dystonia: A five-year follow-up study
  43. Manifestaciones neurológicas en la enfermedad del coronavirus 2019
  44. Neuropsychiatric profile of patients with craniocervical dystonia: A case-control study
  45. Editorial: Patient Empowerment and Person-Centered Care in Movement Disorders
  46. Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson’s Disease
  47. Teaching neurology to “Millennials:” Basic concepts and recommendations
  48. Association Between Somatization and Nonmotor Symptoms Severity in People With Parkinson Disease
  49. Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson’s disease
  50. Review of Hereditary and Acquired Rare Choreas
  51. Factores asociados con deterioro cognitivo en una cohorte mexicana multicéntrica de Parkinson: estudio transversal comparativo
  52. Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al.
  53. Falls in persons with Parkinson's disease: Do non-motor symptoms matter as much as motor symptoms?
  54. Gait in Parkinson’s Disease
  55. Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease
  56. Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly
  57. Incidence rates of Parkinson’s disease in Mexico: Analysis of 2014-2017 statistics
  58. Análisis de subtipos motores en la enfermedad de Parkinson: Registro Mexicano de Enfermedad de Parkinson (ReMePARK)
  59. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations
  60. Influencing factors when living with Parkinson’s disease: A cross‐sectional study
  61. Air Pollution, Multiple Sclerosis and its Relevance to Mexico City
  62. Terapias de infusión en la enfermedad de Parkinson avanzada
  63. The Parkinson's Disease Sleep Scale–2 (PDSS‐2): Validation of the Spanish Version and Its Relationship With a Roommate‐Based Version
  64. Brief historical review of Parkinson’s disease at 200 years of its description
  65. Low diagnostic accuracy of fragile X tremor/ataxia syndrome diagnostic criteria in late onset ataxia
  66. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
  67. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción
  68. Huntington's disease-like disorders in Latin America and the Caribbean
  69. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease
  70. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
  71. Etiología, fenomenología, clasificación y tratamiento de la distonía
  72. Indirect Costs of Parkinson Disease Health Care in the National Institute of Neurology and Neurosurgery in the Mexico City
  73. Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism
  74. Impulse control disorders in Parkinson's: Sleep disorders and nondopaminergic associations
  75. Brain oscillations reveal impaired novelty detection from early stages of Parkinson's disease
  76. Two-hundred Years Later: Is Parkinson�s Disease a Single Defined Entity?
  77. Premotor symptoms and the risk of Parkinson’s disease: A case-control study in Mexican population
  78. Treatable inherited rare movement disorders
  79. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
  80. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative a...
  81. Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population
  82. Spotlight on olfactory dysfunction in Parkinson's disease
  83. Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms
  84. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
  85. Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale
  86. Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings
  87. Living with chronic illness scale: international validation of a new self-report measure in Parkinson’s disease
  88. Analysis of four scales for global severity evaluation in Parkinson’s disease
  89. Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population
  90. Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
  91. Frequency and clinical correlates of postural and striatal deformities in Parkinson’s disease
  92. Parkinson disease and progressive supranuclear palsy: protein expression in skin
  93. A systematic review and mixed treatment comparison of monotherapy in early Parkinson’s disease: implications for Latin America
  94. Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson's disease
  95. Theory of the mind in subjects with Parkinson's disease: A case-control study
  96. Lack of Association between Impulse Control Disorders and REM Sleep Behavior Disorder in Patients with Parkinson’s Disease
  97. Frecuencia de polimorfismos de nucleótido único y haplotipos de alfa-sinucleína asociados con la enfermedad de Parkinson esporádica en población mexicana
  98. Convergent validation of EQ-5D-5L in patients with Parkinson's disease
  99. Delusional Parasitosis as a Treatment Complication of Parkinson Disease
  100. The P3a wave: A reliable neurophysiological measure of Parkinson’s disease duration and severity
  101. No Difference on Adherence Between Immediate-Release Versus Extended-Release Dopamine Agonists in Uninsured Subjects with Parkinson's Disease
  102. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson’s Disease
  103. Electroconvulsive therapy in Parkinson´s disease
  104. Factores asociados a la calidad de vida de sujetos con enfermedad de Parkinson y a la carga en el cuidador
  105. Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers
  106. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study
  107. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
  108. Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease
  109. Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson
  110. A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
  111. Cardiovascular variability in Mexican patients with Parkinson's disease
  112. Impulse control and related disorders in Mexican Parkinson's disease patients
  113. Comparing the accuracy of different smell identification tests in Parkinson’s disease: Relevance of cultural aspects
  114. Simultaneous Presentation of Ocular Flutter in Two Sisters
  115. Clinical, imaging, and molecular findings in a sample of Mexican families with pantothenate kinase-associated neurodegeneration
  116. Comparison of the Montreal Cognitive Assessment and Mini Mental State Examination Performance in Patients with Parkinson’s disease with w Low Educational Background
  117. Vas Eq-5d Utility Index In Parkinson’s Disease
  118. Direct Medical Costs Related To Parkinson’s Disease
  119. A Relationship Between Eq-5d Health State Classifications And Eq Vas Scores In Parkinson’s Disease
  120. A reappraisal of the ten steps test for identifying atypical parkinsonism
  121. Initial circulatory response to active standing in Parkinson's disease without typical orthostatic hypotension
  122. Genetic mutations in early-onset Parkinson's disease Mexican patients: Molecular testing implications
  123. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients
  124. Low specificity and sensitivity of smell identification testing for the diagnosis of Parkinson?s disease
  125. Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA
  126. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  127. Cervical Dystonia
  128. Apathy and associated factors in Mexican patients with Parkinson’s disease
  129. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease
  130. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale
  131. Respuesta ortostática de la tensión arterial de pacientes con enfermedad de Parkinson inicial
  132. Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson’s Disease
  133. Prevalence and determinants of depression in Mexican patients with Parkinson's disease
  134. Overweight is more prevalent in patients with Parkinson's disease
  135. Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies
  136. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease
  137. Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
  138. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease
  139. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  140. A prospective series of patients with hyperglycaemia-associated movement disorders
  141. Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
  142. Relación entre el tipo y lado de inicio de la sintomatología motora con la frecuencia de síntomas no motores en la enfermedad de Parkinson
  143. Involuntary attention impairment in early Parkinson's disease: An event-related potential study
  144. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson's disease
  145. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
  146. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease
  147. Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study
  148. Association of a history of varicella virus infection with multiple sclerosis
  149. Uso clínico de autoanticuerpos en neurología
  150. Quality of life in patients with Parkinson's disease